This K07 award will provide Dr. Jessica Hwang with the experience and mentoring to reach her long-term goal of developing into an independent investigator conducting clinical epidemiology and health services research in internal medicine issues and supportive care of patients undergoing treatment for cancer, particularly in viral reactivation during chemotherapy. Immediate career goals include expanding expertise on reactivation of HBV infection;developing analytic skills, including skills in decision-analysis and cost-effectiveness studies;and gaining expertise in the interpretation of HBV serologic scenarios and the clinical management of patients at risk for reactivation. At present, oncologists in the U.S. perform prechemotherapy screening in only a small percentage of patients at risk for HBV reactivation during chemotherapy. The objective of this application is to determine the impact of systematic prechemotherapy screening for and treatment of HBV among cancer patients undergoing chemotherapy affects clinical outcomes.
The specific aims of this application are to: 1) identify the rates and determinants of serologic screening for HBV among cancer patients receiving chemotherapy at M. D. Anderson Cancer Center;2) determine the rates and predictors of acute HBV infection among M. D. Anderson patients receiving chemotherapy under the current standard of care;3) assess the impact of systematic HBV screening of cancer patients undergoing chemotherapy on the rates of acute HBV infection and related clinical outcomes as compared with a historical cohort;4) develop a decision-analysis model to examine the costs and benefits of preventing reactivation of HBV infection. This study will be the first to systematically examine the impact of HBV screening on outcomes in patients undergoing chemotherapy.
Aims 1 and 2 will be achieved through a retrospective analysis of merged administrative and clinical databases as well as selected chart review;
Aim 3 through a prospective clinical cohort;
and Aim 4 through decision analysis and cost-effectiveness analysis. The combination of Dr. Hwang's unique background in internal medicine and public health and the collective and impressive expertise of her mentoring team make her well suited for conducting this project. The proposed career development activities in cancer control, statistics, decision analysis, and cost-effectiveness analysis will provide Dr. Hwang with the skills necessary to establish herself as an independent researcher in her field.

Public Health Relevance

Nearly 17 million people in the United States have evidence of HBV infection, and they are at high risk for reactivation of HBV infection if they receive immunosuppressive therapy such as chemotherapy. Recent guidelines recommend widespread HBV screening prior to immunosuppression but lack data-driven evidence. This K07 will compare the effectiveness of wide spread vs. targeted HBV screening, and the end result will produce evidence to support HBV screening recommendations for oncologists. These recommendations will inform policy changes and future educational efforts.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Academic/Teacher Award (ATA) (K07)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code
Lu, Huifang; Lok, Anna S; Warneke, Carla L et al. (2018) Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematol 5:e474-e478
Hwang, Jessica P; Lok, Anna S; Fisch, Michael J et al. (2018) Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol :JCO2017756387
Hwang, Jessica P; Suarez-Almazor, Maria E; Cantor, Scott B et al. (2017) Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 123:3367-3376
Hwang, J P; Barbo, A G; Perrillo, R P (2015) Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat 22:346-52
Hwang, Jessica P; Granwehr, Bruno P; Torres, Harrys A et al. (2015) HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. J Oncol Pract 11:384-90
Hwang, Jessica P; Suarez-Almazor, Maria E; Torres, Harrys A et al. (2014) Hepatitis C virus screening in patients with cancer receiving chemotherapy. J Oncol Pract 10:e167-74
Hwang, Jessica P; Lok, Anna S-F (2014) Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11:209-19
Guo, Ying; Jones, Desiree; Palmer, J Lynn et al. (2014) Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 22:1223-31
Hwang, Jessica P; Fisch, Michael J; Lok, Anna S-F et al. (2013) Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 13:534
Yi, Jenny K; Lackey, Susan C; Zahn, Marion P et al. (2013) Human papillomavirus knowledge and awareness among Vietnamese mothers. J Community Health 38:1003-9

Showing the most recent 10 out of 14 publications